Journal of Clinical Oncology, Vol 12, 2405-2414, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

SE Salmon, JJ Crowley, TM Grogan, P Finley, RP Pugh and B Barlogie
University of Arizona Cancer Center, Tucson.

PURPOSE: Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids. Interferon (IFN) alfa maintenance is reported to prolong chemotherapy-induced remissions and survival. This study evaluates induction chemotherapy, glucocorticoids, and interferon maintenance in myeloma. PATIENTS AND METHODS: Five hundred twenty-two previously untreated myeloma patients were randomized to three chemotherapy regimens with differing glucocorticoid intensities. Patients who achieved remission were randomized to receive IFN or observation until relapse. Patients who failed to respond to chemotherapy received IFN alfa plus dexamethasone (DEX). RESULTS: Five hundred nine patients were eligible for induction chemotherapy. Chemotherapy with higher dose-intensity glucocorticoids yielded higher response rates and improved survival (P = .02 for the three-group comparison; P < .05 for each higher glucocorticoid arm v vincristine, melphalan, cyclophosphamide, and prednisone alternating with vincristine, carmustine [BCNU], doxorubicin, and prednisone [VMCP/VBAP]). One hundred ninety-three patients who achieved remission were randomized to receive IFN alfa 3 MU three times weekly or observation. IFN was not superior to observation for relapse-free (P = .95) or overall survival (P = .39) from start of maintenance. Eighty- eight induction failures received 5 MU of IFN three times weekly plus DEX. Patients who received IFN/DEX had a median survival duration of 48 months from start of IFN/DEX. CONCLUSION: Higher-dose glucocorticoids increases frequency of response to chemotherapy and prolong survival in myeloma. IFN maintenance with the dose schedule used in this trial did not prolong relapse-free or overall survival. We cannot exclude a small effect of IFN, as most individual trials do not have sufficient statistical power. Meta-analysis of randomized trials evaluating IFN maintenance in myeloma might be of value. While IFN appeared ineffective, addition of higher-dose glucocorticoids improved outcome in myeloma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B Sirohi, R Powles, D Lawrence, J Treleaven, S Kulkarni, A Leary, C Rudin, C Horton, and G Morgan An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b Ann. Onc., August 1, 2007; 18(8): 1388 - 1394. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				T. Facon, J.-Y. Mary, B. Pegourie, M. Attal, M. Renaud, A. Sadoun, L. Voillat, V. Dorvaux, C. Hulin, G. Lepeu, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy Blood, February 15, 2006; 107(4): 1292 - 1298. [Abstract] [Full Text] [PDF]

				B. G.M. Durie, J. Jacobson, B. Barlogie, and J. Crowley Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials J. Clin. Oncol., May 15, 2004; 22(10): 1857 - 1863. [Abstract] [Full Text] [PDF]

				J. Blade, D. H. Vesole, and M. Gertz Transplantation for multiple myeloma: who, when, how often? Blood, November 15, 2003; 102(10): 3469 - 3477. [Full Text] [PDF]

				S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G Current Therapy for Multiple Myeloma Mayo Clin. Proc., August 1, 2002; 77(8): 813 - 822. [Abstract] [PDF]

				M. LeBlanc, J. Jacobson, and J. Crowley Partitioning and peeling for constructing prognostic groups Statistical Methods in Medical Research, June 1, 2002; 11(3): 247 - 274. [Abstract] [PDF]

				J. R. Berenson, J. J. Crowley, T. M. Grogan, J. Zangmeister, A. D. Briggs, G. M. Mills, B. Barlogie, and S. E. Salmon Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients Blood, May 1, 2002; 99(9): 3163 - 3168. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				M. Massaia, P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, et al. Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy Blood, July 15, 1999; 94(2): 673 - 683. [Abstract] [Full Text] [PDF]

				A. Pulsoni, G. Avvisati, M. Teresa Petrucci, F. Mandelli, D. Giannarelli, V. M. Lauta, M. Tribalto, and A. Pileri The Italian Experience on Interferon as Maintenance Treatment in Multiple Myeloma: Ten Years After Blood, September 15, 1998; 92(6): 2184 - 2186. [Full Text] [PDF]

				R. Bataille and J.-L. Harousseau Multiple Myeloma N. Engl. J. Med., June 5, 1997; 336(23): 1657 - 1664. [Full Text] [PDF]

				B. Barlogie, S. Jagannath, D. H. Vesole, S. Naucke, B. Cheson, S. Mattox, D. Bracy, S. Salmon, J. Jacobson, J. Crowley, et al. Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma Blood, February 1, 1997; 89(3): 789 - 793. [Abstract] [Full Text] [PDF]

				M. Attal, J.-L. Harousseau, A.-M. Stoppa, J.-J. Sotto, J.-G. Fuzibet, J.-F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma N. Engl. J. Med., July 11, 1996; 335(2): 91 - 97. [Abstract] [Full Text] [PDF]